Moolec Science (MLEC) Share-based Compensation (2022 - 2025)
Moolec Science (MLEC) reported Share-based Compensation of $7.3 million for Q4 2025, up 258.21% on a YoY basis from $2.0 million in Q4 2024, and little changed sequentially from $7.3 million in Q2 2025.
Moolec Science (MLEC) Share-based Compensation (2022 - 2025) Analysis & Trends
Moolec Science (MLEC) has 4 years of Share-based Compensation data on file, last reported at $7.3 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation rose 258.21% year-over-year to $7.3 million; the trailing twelve-month figure through Dec 2025 stood at $7.3 million (up 258.21% YoY), and the FY2025 full-year result was $7.3 million, down 48.79% from the prior year.
- Share-based Compensation was little changed at $7.3 million in Q4 2025, from $7.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $15.9 million in Q2 2024 to a low of $63876.0 in Q2 2022.
- A 4-year average of $3.6 million and a median of $2.2 million in 2023 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation jumped 5227.35% in 2023 and tumbled 54.3% in 2025, its largest moves.
- Tracing MLEC's Share-based Compensation over 4 years: stood at $551841.0 in 2022, then soared by 298.92% to $2.2 million in 2023, then slipped by 7.34% to $2.0 million in 2024, then jumped by 258.21% to $7.3 million in 2025.
- Business Quant data shows MLEC's Share-based Compensation at $7.3 million in Q4 2025, $7.3 million in Q2 2025, and $2.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 305,000.00 |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | - |
| 10 | Moolec Science | 5.35 Bn | 5.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.31 Mn |
| Dec 31, 2025 | 7.31 Mn |
| Jun 30, 2025 | 7.27 Mn |
| Jun 30, 2025 | 7.27 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 15.91 Mn |
| Jun 30, 2024 | 15.91 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Mar 31, 2024 | 2.97 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Sep 30, 2023 | 1.74 Mn |
| Sep 30, 2023 | 1.74 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 154,235.00 |
| Mar 31, 2023 | 154,235.00 |